Details of the Drug Combination

General Information of Drug Combination (ID: DCIIIUH)

Drug Combination Name
JZL195 Daidzin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs JZL195   DMEOCKZ Daidzin   DMFCMPS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 56.02
Bliss Independence Score: 56.02
Loewe Additivity Score: 70.49
LHighest Single Agent (HSA) Score: 70.49

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of JZL195
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
JZL195 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Acyloxyacyl hydrolase (neutrophil) TT2EJXQ AOAH_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Daidzin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mitochondrial aldehyde dehydrogenase (ALDH2) TTFLN4T ALDH2_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Daidzin Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [4]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Increases Expression [4]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 Intestinal bacteria activate estrogenic effect of main constituents puerarin and daidzin of Pueraria thunbergiana. Biol Pharm Bull. 2006 Dec;29(12):2432-5. doi: 10.1248/bpb.29.2432.